Full-Time

Lead Director

Performance Analytics & Optimization

Deadline 9/19/26
CVS Health

CVS Health

10,001+ employees

Healthcare, insurance, PBM, and retail pharmacy

Compensation Overview

$100k - $231.5k/yr

+ Bonus + Commission + Short-term incentive + Equity award

Company Historically Provides H1B Sponsorship

Kansas, USA + 23 more

More locations: Pennsylvania, USA | Delaware, USA | Connecticut, USA | Texas, USA | Florida, USA | Georgia, USA | Arizona, USA | Tennessee, USA | Virginia, USA | Colorado, USA | Rhode Island, USA | Kentucky, USA | New York, NY, USA | Maryland, USA | Massachusetts, USA | North Carolina, USA | Oklahoma, USA | Ohio, USA | New Jersey, USA | Indiana, USA | Louisiana, USA | Illinois, USA | Alabama, USA

Remote

Bachelor's

Category
Data & Analytics
Required Skills
Power BI
Data Visualization
Financial analysis
Quality Assurance (QA)
Data Analysis
Google Cloud Platform

Get referred to CVS Health

See people who can refer or advise you

Requirements
  • At least 5 years of progressive experience in healthcare, Payment Integrity, claims, analytics, data, operations, or a related field.
  • At least 5 years of leadership experience managing teams and/or complex enterprise programs.
  • Demonstrated experience leading analytics-driven performance management.
  • Experience working with large, complex datasets and translating data into business decisions.
  • Experience developing executive dashboards and performance reporting.
  • A bachelor's degree in Business, Analytics, Data Science, Healthcare Administration, Finance, Information Systems, or related work experience is required.
Responsibilities
  • Establish and maintain a standardized performance measurement framework across all Payment Integrity editing platforms.
  • Monitor edit performance following deployment and throughout the edit lifecycle.
  • Develop and maintain key performance indicators and performance scorecards for the editing portfolio.
  • Analyze trends in claims, savings, utilization, provider behavior, and edit outcomes.
  • Identify underperforming, overperforming, or anomalous edits requiring investigation.
  • Establish performance thresholds and triggers for optimization or remediation.
  • Provide executive-level reporting and insights to Payment Integrity leadership.
  • Own the independent measurement and validation of edit savings.
  • Monitor expected versus realized savings following deployment.
  • Identify variance between projected and actual financial performance.
  • Partner with Finance and Payment Integrity leadership to establish consistent savings methodologies.
  • Ensure savings reporting is accurate, transparent, repeatable, and supported by data.
  • Identify opportunities to improve savings realization through optimization.
  • Establish an independent quality assurance framework for deployed edits.
  • Monitor edit accuracy and effectiveness across GCP, Lyric, Cotiviti, and other editing solutions.
  • Evaluate whether edits are producing the intended outcome after deployment.
  • Identify quality defects, unintended outcomes, and opportunities for remediation.
  • Establish quality standards, sampling methodologies, and ongoing monitoring practices.
  • Provide objective feedback to editing and solution design teams.
  • Establish enterprise standards for measuring edit precision, recall, and false-positive rates.
  • Monitor edits for inappropriate or unnecessary claim impacts.
  • Identify edits with high false-positive rates or unfavorable provider/member impact.
  • Partner with editing teams to determine appropriate optimization strategies.
  • Balance financial opportunity with edit accuracy, provider experience, and operational efficiency.
  • Establish a structured continuous optimization process for the editing portfolio.
  • Identify opportunities to modify, refine, expand, reduce, or retire edits based on performance data.
  • Develop optimization recommendations based on empirical performance rather than anecdotal feedback.
  • Establish post-deployment review cycles and performance thresholds.
  • Ensure optimization activities are prioritized based on financial impact, quality, risk, and operational value.
  • Track optimization recommendations through completion and measure resulting impact.
  • Establish a centralized performance reporting strategy for Payment Integrity editing.
  • Oversee development and maintenance of Power BI dashboards and executive reporting.
Desired Qualifications
  • Experience with healthcare claims data and payment integrity is strongly preferred.
  • Experience with claims editing, prepay/post-pay processes, or claims platforms is strongly preferred.
  • Demonstrated experience with continuous improvement and optimization methodologies.

CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Woonsocket, Rhode Island

Founded

1963

Get referred to CVS Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $106.1 billion, up 7.3%, with adjusted EPS $2.58.
  • CVS raised 2026 adjusted EPS guidance to $7.90-$8.10 and cash flow to $11.5 billion.
  • Walgreens' 1,200-store closures through 2027 funnel prescriptions toward CVS locations.

What critics are saying

  • FTC settlement on Caremark insulin practices forces transparency changes through 2036.
  • CVS expects 340B pressure and Caremark membership declines in 2027.
  • $175 billion liabilities and $3.12 billion annual interest burden constrain strategic flexibility.

What makes CVS Health unique

  • Caremark, Aetna, and 9,000 stores create unmatched U.S. pharmacy-insurance integration.
  • CVS handled 87 million PBM members and 37 million insured people in June 2026.
  • CVS app now prices Eli Lilly Zepbound and Mounjaro for same-day pickup.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Company Equity

Wellness Program

Professional Development Budget

Paid Vacation

Paid Holidays

Company News

Yahoo Finance
Sep 12th, 2026
CVS quietly gains market share as Walgreens closes 1,200 US stores following $10B private equity sale

Walgreens is closing roughly 1,200 of its approximately 8,500 US locations through 2027, with many customers being redirected to nearby CVS pharmacies. The pattern is reshaping suburban pharmacy markets without direct competition. In August 2025, Walgreens completed a $10 billion sale to private equity firm Sycamore Partners, taking the 124-year-old chain private for the first time. Mike Motz was named chief executive, replacing Tim Wentworth. CVS is gaining market share without active expansion efforts. Federal and state rules require orderly prescription transfers when pharmacies close, often directing patients to the nearest CVS location. CVS and Walgreens together now handle nearly 40% of all US retail prescription sales. CVS benefits from owning Caremark, a dominant pharmacy benefit manager, providing vertical integration advantages.

Yahoo Finance
Aug 28th, 2026
CVS stock down 12% in a month despite 34% annual gain, faces 2027 headwinds

CVS Health stock has declined 12.3% over the past month, sitting about 15% below its 52-week high, though it remains up 34% over the trailing twelve months. The company's revenue reached approximately $415 billion, up 7.4% year-over-year. Management raised its full-year 2026 adjusted earnings per share guidance by $0.60 to a range of $7.90 to $8.10. For 2027, the company anticipates membership declines at Caremark and continued 340B programme pressure, offset by Aetna's recovery, which added over $2 billion in adjusted operating income in the first half of 2026. Management considers a 2027 adjusted EPS outlook of at least $8.44 reasonable. Historically, CVS has experienced varied recovery periods following market downturns, with some rebounds taking years rather than months.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.

Yahoo Finance
Aug 19th, 2026
CVS Health appoints JPMorgan data executive to board as focus shifts to digital healthcare

CVS Health has appointed Teresa Heitsenrether, a senior executive from JPMorgan Chase with extensive data and analytics experience, to its board of directors. The move follows the resignation of board member Larry M. Robbins. The appointment signals CVS Health's focus on technology and data-driven healthcare at the governance level. The company, valued at approximately $120bn, operates an integrated healthcare model spanning insurance, pharmacy benefits, and retail services. Heitsenrether's data expertise aligns with CVS Health's strategy to leverage digital capabilities and operational efficiency across its businesses, including Aetna and Caremark. The company faces challenges including high debt levels and reimbursement pressures in a competitive market alongside UnitedHealth Group and Cigna.

Yahoo Finance
Aug 14th, 2026
CVS Health beats Q2 revenue and profit estimates but faces questions on sustainability

CVS Health reported second quarter revenue of $106.1 billion, beating analyst estimates of $99.41 billion by 6.7%. Adjusted earnings per share came in at $2.58, surpassing expectations of $1.85 by 39.4%. Management attributed strong performance to specialty pharmacy and Medicare Advantage, with CEO David Joyner noting improvements from actions taken in Aetna and Caremark. The company raised its full-year adjusted EPS guidance to $8 at the midpoint. However, analysts raised concerns about sustainability. Management acknowledged ongoing challenges in the 340B program and normalisation of script share gains from Rite Aid. To offset these headwinds, executives pointed to biosimilars and investments in service technology. The company has committed $20 billion over a decade to AI and technology investments, with operational savings already being realised.